Evidence map›Paper›PMID 40781203›Full record

ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026

Comparing EQ-5D-5L and SF-6Dv2 utilities with QLU-C10D utilities in hematologic cancer patients.

Tiantian Zhang, Aixue Zhang, Jing Li, Fangyu Li, Peng Liu, Pei Wang

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tiantian Zhang *College of Pharmacy, Jinan University, Guangzhou, China.
Aixue Zhang *School of Public Health, Fudan University, 130 Dong An Road, Shanghai, 200032, China.
Jing Li *Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
Fangyu LiSchool of Public Health, Fudan University, 130 Dong An Road, Shanghai, 200032, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China. liu.peng@zs-hospital.sh.cn.
Pei WangSchool of Public Health, Fudan University, 130 Dong An Road, Shanghai, 200032, China. wang_p@fudan.edu.cn.ORCID http://orcid.org/0000-0003-3661-3944

Funding

National Natural Science Foundation of China 72274037
6 · The paper itself

Abstract

objectivesTo compare the measurement properties between EQ-5D-5L/SF-6Dv2 and QLU-C10D utilities, and to assess the implications of their adoption in QALY estimation in hematologic cancer patients.

methodLongitudinal data of Chinese lymphoma and myeloma patients were adopted. Utility scores of the three instruments were calculated based on a variety of country-specific value sets. Their measurement properties including convergent validity, known-group validity, sensitivity, and responsiveness were compared. With-in group change in utilities derived from the instruments were also generated and compared.

resultsA total of 200 lymphoma and 139 myeloma patients were enrolled at baseline; and 78 and 89 of them were followed up, respectively. The three kinds of utilities showed similar convergent validity; but all had restricted known-group validity. All of them could identify meaningful changes in clinical status; while whether QLU-C10D utilities was more responsive and yielded larger utility change were closely related to the value sets adopted.

conclusionIt appears that the advantages of QLU-C10D over EQ-5D-5L/SF-6Dv2 were not so obvious, and it may not necessarily produce more QALY gains as well. The choice of utility value set played an important role in the two aspects.

Indexed as

Hematologic NeoplasmsLymphomaMultiple MyelomaQuality-Adjusted Life YearsQuality of LifeAdultAgedChinaFemaleHealth StatusHumansLongitudinal StudiesMaleMiddle AgedReproducibility of ResultsSurveys and QuestionnairesEQ-5D-5LHealth UtilityHematologic cancerQLU-C10DSF-6Dv2

Identifiers

PMID40781203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.